



## SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for oral and poster presentations at the AACR Annual Meeting, which will take place April 12-16 in San Diego, California.

An oral presentation by Dr. Steven Warner will highlight SuperGen's PIM Kinase Inhibitor in cell lines from hematological and solid malignancies. The poster presentations will focus on data concerning many of SuperGen's current oncology programs, including the lead clinical compound, MP-470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.

SuperGen's schedule of presentations is as follows:

Date	Time (PDT)	Abstract # and Title
Sunday, April 13	8 a.m. - 12 p.m.	#671 -- Inhibition of erlotinib resistance on HER-family tyrosine kinases by combination with MP-470, a multi-targeted TK inhibitor in prostate and breast cancer
Monday, April 14	1 p.m. - 5 p.m.	#2613 -- The dinucleotide prodrug of decitabine demonstrated increased in vivo efficacy due to enhanced drug delivery and stability
Tuesday, April 15	8 a.m. - noon	#4083 -- MP-470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study
Tuesday, April 15	2:25 p.m. - 2:40 p.m. (oral presentation)	#4974 -- A potent small molecule PIM kinase inhibitor with activity in cell lines from hematological and solid malignancies
Tuesday, April 15	1 p.m. - 5 p.m.	#4891 -- Activity of the multi-targeted, receptor tyrosine kinase inhibitor MP-470 against synovial sarcoma cells
Wednesday, April 16	8 a.m. - noon	#5729 -- Pharmacokinetics of MP-529, a selective Aurora A kinase inhibitor, in a novel subcutaneous delivery system

### About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

### Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

#### Contacts

Timothy L. Enns  
SuperGen, Inc.  
SVP, Corporate Communications  
& Business Development  
Tel: (925) 560-0100  
E-mail: [tenns@supergen.com](mailto:tenns@supergen.com)

Mary M. Vegh  
SuperGen, Inc.  
Manager, Investor Relations  
Tel: (925) 560-2845  
E-mail: [mary.vegh@supergen.com](mailto:mary.vegh@supergen.com)

SOURCE SuperGen Inc.  
Web site: <http://www.supergen.com>  
<http://www.prnewswire.com>